Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 09 09 2020
accepted: 22 02 2021
pubmed: 19 3 2021
medline: 3 8 2021
entrez: 18 3 2021
Statut: ppublish

Résumé

To determine the primary reason for hospitalisations in systemic sclerosis (SSc) and impact of underlying interstitial lung disease (ILD) in a tertiary scleroderma centre. A retrospective analysis on a subset of a scleroderma cohort from 2011-2019 was performed to assess causes for hospitalisations and mortality. A chart review was performed to extract demographics, primary reason for hospitalisation and inpatient mortality. Admissions were classified as SSc (if hospitalisation reason was related to primary organ dysfunction) and non-SSc related causes. The mean age of the cohort was 53.1 years, 78% were women, and the mean disease duration was 5.2 years. Among 484 patients, 182 (37.6%) were admitted for a total of 634 admissions. In 382 SSc-related admissions, pulmonary hypertension (12.0%) and gastrointestinal dysmotility (11.0%), were major causes of urgent admissions; management of digital vasculopathy (26.1%) was the major reason for elective admissions. In 252 non-SSc related admissions, infection (respiratory:11.5%, skin and soft tissue: 6.3%) was the major reason for urgent admissions, and elective surgery (21.4%) was the major reason for elective admissions. We found 65% of all patients had underlying ILD and a greater proportion of patients with ILD were hospitalised (122 patients). Overall inpatient mortality was 9.3% and the leading cause for mortality was progressive pulmonary hypertension. Among a large cohort of SSc patients who are followed at a tertiary scleroderma centre, 37.6 % had hospital admissions, while worsening pulmonary hypertension, ILD, cardiac involvement and infectious complications were the major cause of mortality and morbidity.

Identifiants

pubmed: 33734968
pii: 16427
pmc: PMC8324531
mid: NIHMS1709845
doi: 10.55563/clinexprheumatol/9ivp9g
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-51

Subventions

Organisme : NIAMS NIH HHS
ID : K24 AR063120
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR070470
Pays : United States
Organisme : NIAMS NIH HHS
ID : T32 AR007080
Pays : United States

Références

Ann Rheum Dis. 2010 Oct;69(10):1809-15
pubmed: 20551155
Cureus. 2018 May 14;10(5):e2628
pubmed: 30027020
Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660
pubmed: 31841044
Rheumatology (Oxford). 2007 Dec;46(12):1808-13
pubmed: 17986481
Arthritis Rheumatol. 2019 Aug;71(8):1339-1349
pubmed: 30762947
Clin Rheumatol. 2013 Mar;32(3):361-7
pubmed: 23224269
Curr Opin Rheumatol. 2019 May;31(3):241-249
pubmed: 30870216
Rheumatology (Oxford). 2018 Sep 1;57(9):1611-1622
pubmed: 29868788
Cochrane Database Syst Rev. 2000;(2):CD000953
pubmed: 10796395
Reumatologia. 2017;55(4):163-168
pubmed: 29056770
Lancet. 2017 Oct 7;390(10103):1685-1699
pubmed: 28413064
Rheumatol Int. 2016 Jan;36(1):73-81
pubmed: 26211000
Curr Opin Rheumatol. 2020 May;32(3):228-237
pubmed: 32205570
J Rheumatol. 2018 Feb;45(2):235-241
pubmed: 29142033
Clin Rheumatol. 2016 Jun;35(6):1631-5
pubmed: 27056049
Arthritis Rheumatol. 2020 Jul;72(7):1049-1058
pubmed: 32134199
Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):3-14
pubmed: 31587697
Semin Arthritis Rheum. 2020 Jun;50(3):473-479
pubmed: 31810742
Int J Rheum Dis. 2020 Feb;23(2):137-139
pubmed: 32043307
Eur Respir J. 2019 Aug 22;54(2):
pubmed: 31196948

Auteurs

Shobana Sankar (S)

Department of Medicine, William Beaumont Hospital, Royal Oak, USA.

Mirette Habib (M)

Division of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.

Sara Jaafar (S)

Division of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.

Vivek Nagaraja (V)

Division of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.

David Roofeh (D)

Division of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.

Amber Young (A)

Division of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA.

Suiyuan Huang (S)

Division of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, and School of Public Health, University of Michigan Medical School, Ann Arbor, USA.

Dinesh Khanna (D)

Division of Rheumatology, Department of Medicine, University of Michigan Medical School, Ann Arbor, USA. khannad@med.umich.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH